Current treatment strategy for newly diagnosed chordoma of the mobile spine and sacrum: results of an international survey

Restricted access


The purpose of this study was to investigate the spectrum of current treatment protocols for managing newly diagnosed chordoma of the mobile spine and sacrum.


A survey on the treatment of spinal chordoma was distributed electronically to members of the AOSpine Knowledge Forum Tumor, including neurosurgeons, orthopedic surgeons, and radiation oncologists from North America, South America, Europe, Asia, and Australia. Survey participants were pre-identified clinicians from centers with expertise in the treatment of spinal tumors. The suvey responses were analyzed using descriptive statistics.


Thirty-nine of 43 (91%) participants completed the survey. Most (80%) indicated that they favor en bloc resection without preoperative neoadjuvant radiation therapy (RT) when en bloc resection is feasible with acceptable morbidity. The main area of disagreement was with the role of postoperative RT, where 41% preferred giving RT only if positive margins were achieved and 38% preferred giving RT irrespective of margin status. When en bloc resection would result in significant morbidity, 33% preferred planned intralesional resection followed by RT, and 33% preferred giving neoadjuvant RT prior to surgery. In total, 8 treatment protocols were identified: 3 in which en bloc resection is feasible with acceptable morbidity and 5 in which en bloc resection would result in significant morbidity.


The results confirm that there is treatment variability across centers worldwide for managing newly diagnosed chordoma of the mobile spine and sacrum. This information will be used to design an international prospective cohort study to determine the most appropriate treatment strategy for patients with spinal chordoma.

ABBREVIATIONS HRQOL = health-related quality of life; RT = radiation therapy.

Article Information

Correspondence Nicolas Dea: Vancouver General Hospital and The University of British Columbia, Vancouver, BC, Canada.

INCLUDE WHEN CITING Published online October 19, 2018; DOI: 10.3171/2018.6.SPINE18362.

Disclosures Dr. Dea reports consultant relationships with Medtronic, Baxter, and Stryker and direct stock ownership in Medtronic. Dr. Fisher reports consultant relationships with Medtronic and NuVasive as well as receipt of royalties from Medtronic. Dr. Rhines reports an educational relationship with Stryker. Dr. Gokaslan reports direct stock ownership in Spinal Kinetics. Dr. Sahgal reports the following financial relationships: educational seminars with Elekta AB, Accuray Inc, and Varian Medical Systems; a research grant from Elekta AB; and travel accommodations/expenses from Elekta and Varian. Dr. Sahgal also reports belonging to the Elekta MR Linac Research Consortium. Dr. Laufer reports consultant relationships with Globus, Medtronic, DePuy/Synthes, Spinewave, and Brainlab. Ms. Germscheid reports an employee relationship with AOSpine International.

© AANS, except where prohibited by US copyright law.



  • View in gallery

    Results for the first question: What is your preferred treatment strategy for a newly diagnosed chordoma of the spine when en bloc resection is feasible with acceptable morbidity?

  • View in gallery

    Results for the second question: What is your preferred treatment strategy for newly diagnosed chordoma of the spine when en bloc resection would result in significant morbidity (upper cervical, high sacrectomy)?

  • View in gallery

    Proposed treatment pathways for a prospective cohort study.


  • 1

    Boriani SBandiera SBiagini RBacchini PBoriani LCappuccio M: Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) 31:4935032006

  • 2

    Boriani SSaravanja DYamada YVarga PPBiagini RFisher CG: Challenges of local recurrence and cure in low grade malignant tumors of the spine. Spine (Phila Pa 1976) 34 (22 Suppl):S48S572009

  • 3

    Charest-Morin RDea NFisher CG: Health-related quality of life after spine surgery for primary bone tumour. Curr Treat Options Oncol 17:92016

  • 4

    Chen YLLiebsch NKobayashi WGoldberg SKirsch DCalkins G: Definitive high-dose photon/proton radiotherapy for unresected mobile spine and sacral chordomas. Spine (Phila Pa 1976) 38:E930E9362013

  • 5

    Dea NCharest-Morin RSciubba DMBird JEDisch ACMesfin A: Optimizing the adverse event and HRQOL profiles in the management of primary spine tumors. Spine (Phila Pa 1976) 41 (Suppl 20):S212S2172016

  • 6

    DeLaney TFLiebsch NJPedlow FXAdams JWeyman EAYeap BY: Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 110:1151222014

  • 7

    Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res (204):9241986

  • 8

    Fisher CGGoldschlager TBoriani SVarga PPRhines LDFehlings MG: An evidence-based medicine model for rare and often neglected neoplastic conditions. J Neurosurg Spine 21:7047102014

  • 9

    Fuchs BDickey IDYaszemski MJInwards CYSim FH: Operative management of sacral chordoma. J Bone Joint Surg Am 87:221122162005

  • 10

    Gokaslan ZLZadnik PLSciubba DMGermscheid NGoodwin CRWolinsky JP: Mobile spine chordoma: results of 166 patients from the AOSpine Knowledge Forum Tumor database. J Neurosurg Spine 24:6446512016

  • 11

    Goodwin CRAbu-Bonsrah NBilsky MHReynolds JJRhines LDLaufer I: Clinical decision making: integrating advances in the molecular understanding of spine tumors. Spine (Phila Pa 1976) 41 (Suppl 20):S171S1772016

  • 12

    Imai RKamada TTsuji HSugawara SSerizawa ITsujii H: Effect of carbon ion radiotherapy for sacral chordoma: results of Phase I-II and Phase II clinical trials. Int J Radiat Oncol Biol Phys 77:147014762010

  • 13

    Indelicato DJRotondo RLBegosh-Mayne DScarborough MTGibbs CPMorris CG: A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys 95:2973032016

  • 14

    Kabolizadeh PChen YLLiebsch NHornicek FJSchwab JHChoy E: Updated outcome and analysis of tumor response in mobile spine and sacral chordoma treated with definitive high-dose photon/proton radiation therapy. Int J Radiat Oncol Biol Phys 97:2542622017

  • 15

    Molina CAAmes CPChou DRhines LDHsieh PCZadnik PL: Outcomes following attempted en bloc resection of cervical chordomas in the C-1 and C-2 region versus the subaxial region: a multiinstitutional experience. J Neurosurg Spine 21:3483562014

  • 16

    Nishida YKamada TImai RTsukushi SYamada YSugiura H: Clinical outcome of sacral chordoma with carbon ion radiotherapy compared with surgery. Int J Radiat Oncol Biol Phys 79:1101162011

  • 17

    Park LDelaney TFLiebsch NJHornicek FJGoldberg SMankin H: Sacral chordomas: impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. Int J Radiat Oncol Biol Phys 65:151415212006

  • 18

    Pennicooke BLaufer ISahgal AVarga PPGokaslan ZLBilsky MH: Safety and local control of radiation therapy for chordoma of the spine and sacrum: a systematic review. Spine (Phila Pa 1976) 41 (Suppl 20):S186S1922016

  • 19

    Reynolds JJKhundkar RBoriani SWilliams RRhines LDKawahara N: Soft tissue and bone defect management in total sacrectomy for primary sacral tumors: a systematic review with expert recommendations. Spine (Phila Pa 1976) 41 (Suppl 20):S199S2042016

  • 20

    Rotondo RLFolkert WLiebsch NJChen YLEPedlow FXSchwab JH: High-dose proton-based radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. J Neurosurg Spine 23:7887972015

  • 21

    Ruggieri PAngelini AUssia GMontalti MMercuri M: Surgical margins and local control in resection of sacral chordomas. Clin Orthop Relat Res 468:293929472010

  • 22

    Schwab JHJanssen SJPaulino Pereira NRChen YLEWain JCDeLaney TF: Quality of life after resection of a chordoma of the mobile spine. Bone Joint J 99-B:9799862017

  • 23

    Stacchiotti SCasali PG: Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep 13:3233302011

  • 24

    van Wulfften Palthe ODRHoudek MTRose PSYaszemski MJSim FHBoland PJ: How does the level of nerve root resection in en bloc sacrectomy influence patient-reported outcomes? Clin Orthop Relat Res 475:6076162017

  • 25

    van Wulfften Palthe ODRJanssen SJWunder JSFerguson PCWei GRose PS: What questionnaires to use when measuring quality of life in sacral tumor patients: the updated sacral tumor survey. Spine J 17:6366442017

  • 26

    Varga PPSzövérfi ZFisher CGBoriani SGokaslan ZLDekutoski MB: Surgical treatment of sacral chordoma: prognostic variables for local recurrence and overall survival. Eur Spine J 24:109211012015

  • 27

    Verlaan JJKuperus JSSlooff WBHennipman AOner FC: Complications, secondary interventions and long term morbidity after en bloc sacrectomy. Eur Spine J 24:220922192015

  • 28

    Wei FLiu ZLiu XJiang LDang GPassias PG: An approach to primary tumors of the upper cervical spine with spondylectomy using a combined approach: our experience with 19 cases. Spine (Phila Pa 1976) 43:81882018

  • 29

    Yamada YLaufer ICox BWLovelock DMMaki RGZatcky JM: Preliminary results of high-dose single-fraction radiotherapy for the management of chordomas of the spine and sacrum. Neurosurgery 73:6736802013




All Time Past Year Past 30 Days
Abstract Views 449 449 52
Full Text Views 134 134 19
PDF Downloads 113 113 20
EPUB Downloads 0 0 0


Google Scholar